Zynerba Pharmaceuticals (NASDAQ: ZYNE) and OncoSec Medical (NASDAQ:ONCS) are both small-cap biotechnology & medical research – nec companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, valuation, analyst recommendations, earnings, institutional ownership, risk and dividends.

Valuation & Earnings

This table compares Zynerba Pharmaceuticals and OncoSec Medical’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Zynerba Pharmaceuticals $10,000.00 18,807.40 -$23.38 million ($2.59) -5.36
OncoSec Medical N/A N/A -$21.44 million ($1.06) -1.99

OncoSec Medical has higher revenue, but lower earnings than Zynerba Pharmaceuticals. Zynerba Pharmaceuticals is trading at a lower price-to-earnings ratio than OncoSec Medical, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

34.7% of Zynerba Pharmaceuticals shares are held by institutional investors. Comparatively, 8.6% of OncoSec Medical shares are held by institutional investors. 10.0% of Zynerba Pharmaceuticals shares are held by insiders. Comparatively, 11.5% of OncoSec Medical shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and target prices for Zynerba Pharmaceuticals and OncoSec Medical, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Zynerba Pharmaceuticals 0 5 4 0 2.44
OncoSec Medical 0 0 5 0 3.00

Zynerba Pharmaceuticals currently has a consensus price target of $15.13, indicating a potential upside of 8.97%. OncoSec Medical has a consensus price target of $5.33, indicating a potential upside of 152.76%. Given OncoSec Medical’s stronger consensus rating and higher probable upside, analysts plainly believe OncoSec Medical is more favorable than Zynerba Pharmaceuticals.

Profitability

This table compares Zynerba Pharmaceuticals and OncoSec Medical’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Zynerba Pharmaceuticals N/A -51.73% -46.11%
OncoSec Medical N/A -122.05% -97.52%

Summary

OncoSec Medical beats Zynerba Pharmaceuticals on 6 of the 10 factors compared between the two stocks.

Zynerba Pharmaceuticals Company Profile

Zynerba Pharmaceuticals, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing transdermal synthetic cannabinoid treatments for patients with high unmet needs. Its development pipeline includes two product candidates: ZYN002 and ZYN001. ZYN002 is a synthetic cannabidiol (CBD), which is a non-psychoactive cannabinoid, formulated as a patent-protected permeation-enhanced gel for transdermal delivery through the skin and into the circulatory system. ZYN002 is in Phase II clinical development in patients with refractory epilepsy, in patients with osteoarthritis of the knee, as well as in patients with Fragile X syndrome. ZYN001 is a pro-drug of tetrahydrocannabinol (THC) that enables transdermal delivery through the skin and into the circulatory system through a patch. ZYN001 is targeting two pain indications, fibromyalgia and peripheral neuropathic pain.

OncoSec Medical Company Profile

OncoSec Medical Incorporated is a biotechnology company. The Company is focused on designing, developing and commercializing gene therapies, therapeutics and medical approaches to stimulate an anti-tumor immune response for the treatment of cancer. The Company’s lead product candidate, ImmunoPulse IL-12, consists of a plasmid construct encoding the proinflammatory cytokine, IL-12, which is delivered into the tumor through in vivo electroporation. As of July 31, 2016, the Company was pursuing two Phase II trials: ImmunoPulse IL-12 monotherapy in patients with metastatic melanoma and ImmunoPulse IL-12 plus pembrolizumab in patients with advanced, metastatic melanoma. In addition, it is pursuing ImmunoPulse IL-12 monotherapy in patients with triple negative breast cancer. Its ImmunoPulse product candidates are based on its deoxyribonucleic acid (DNA)-based immunotherapy technology, which is designed to stimulate the human immune system, resulting in systemic anti-tumor immune responses.

Receive News & Ratings for Zynerba Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zynerba Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.